Jump to Main Content


Schedule and Program for the 2023 ASH Meeting on Hematologic Malignancies

The following program corresponds to the 2023 ASH Meeting on Hematologic Malignancies. All sessions listed are in Central time.

Program Schedule

 7:00 a.m.  Breakfast / Exhibits / Registration
7:50 a.m.
Welcome and Introductions
8:00 a.m. How I Test and Manage CHIP/CCUS

Abhay Singh, MD
Cleveland Clinic
(Cleveland, Ohio)
8:30 a.m. How I Treat Patients with MDS: Clinical Trials

Mikkael Sekeres, MD
University of Miami
(Miami, Florida)
9:00 a.m. Case-Based Panel Discussion
9:45 a.m. Networking Coffee Break and Exhibits
10:15 a.m. How I Treat Ph+ ALL

Anjali Advani, MD 
Cleveland Clinic
(Cleveland, Ohio) 
10:45 a.m. How I Treat Ph Negative B-ALL in Older Patients 

Ibrahim Aldoss, MD
City of Hope Medical Center
(Duarte, California) 
11:15 a.m. Panel Discussion  
11:45 a.m. Lunch with the Experts Session 
1:00 p.m. How I Select Transplant for Patients with AML

Partow Kebriaei, MD
MD Anderson Cancer Center
(Houston, Texas)  
1:30 p.m. Q&A with speaker 
1:45 p.m. Special Education Session: How I Treat a Newly Diagnosed Older Patient

Jacqueline Garcia, MD, Dana Farber Cancer Institute (Boston, Massachusetts)
Michael Keng, MD, University of Virginia (Charlottesville, Virginia)
Uma Borate, MD, Ohio State University (Columbus, Ohio)
3:30 p.m. Networking Coffee Break and Exhibits
4:00 p.m. How I Navigate Unique Situations in Polycythemia Vera and Essential Thrombocythemia

Brady L. Stein, MD
Northwestern University
(Chicago, Illinois)
4:30 p.m. How I Approach Myelofibrosis Treatment in 2023 and Beyond

Elizabeth Hexner, MD, MSTR
University of Pennsylvania
(Philadelphia, Pennsylvania)
5:00 p.m. Panel Discussion
5:30 p.m. Meeting Day 1 Adjourns
6:00 p.m. - 8:00 p.m.

Satellite Symposia

Bruton Tyrosine Kinase Inhibitors in CLL: Case Challenges and Clinical Insights

How We Do It®:Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma

7:00 a.m.  Breakfast / Exhibits / Registration
7:50 a.m.  Welcome and Introductions
8:00 a.m. Is There Still a Role for Auto SCT in Mantle Cell Lymphoma in 2023?

Michael Williams, MD, MSc
University of Virginia
(Charlottesville, Virginia)
8:30 a.m. PET-Adapted Treatment of Early-Stage Hodgkin Lymphoma: Preserving Cures, Reducing Risk

Nina Wagner-Johnston, MD
Johns Hopkins Medicine
(Baltimore, Maryland)
9:00 a.m. Bispecific T-Cell Engaging Antibodies in Relapsed Lymphoma: A New Era Has Arrived

Tycel Phillips, MD
City of Hope
(Duarte, California) 
9:30 a.m. Panel Discussion 
10:00 a.m. Networking Coffee Break and Exhibits
10:30 a.m. Should Time-Limited Front-Line Therapy Be the New Standard in CLL?

Jan Burger, MD, PhD
MD Anderson Cancer Center
(Houston, Texas)
11:00 a.m. Which BTK Inhibitor in Front-Line and Relapsed CLL Treatment?

John Allan, MD
Weill Cornell Medicine
(New York, New York)
11:30 a.m. Panel Discussion 
12:00 p.m. Lunch with the Experts Session 
1:15 p.m. Is There Still a Role for Transplant in MM?

Shaji Kumar, MD
Mayo Clinic
(Rochester, Minnesota)
1:45 p.m. Optimizing Treatment for Frailty in MM

Ashley Rosko, MD
Ohio State University
(Columbus, Ohio) 
2:15 p.m. Panel Discussion
2:45 p.m. Networking Coffee Break and Exhibits
3:15 p.m. Where Do I Use Immunotherapy in Myeloma?

Noopur Raje, MD
Massachusetts General Hospital
(Boston, Massachusetts)
3:45 p.m. How Do I Manage Immunotherapy Related Toxicity?

Shambavi Richard, MD
Mount Sinai
(New York, New York)
4:15 p.m. Panel Discussion
4:45 p.m. Program Adjournment 

Explore MHM 2023